New OHE insight on immunisation: despite high returns on investment, global spending lags. We outline why and how countries ...

Analysis of Trump’s ‘Most Favoured Nation’ Executive Order on drug pricing, its global impact, price convergence aims, and ...

Neil McAuslane PhD, MSc, BSc. Scientific Director of the Centre for Innovation in Regulatory Science (CIRS) overseeing the scientific content of both CIRS regulatory and HTA programmes. Key research ...

Kiran Bhatti joined OHE in March 2025 as a Business Executive. She holds an MBA Master of Business Administration degree. She is a finance professional with over 18 years’ experience in business ...

Despite substantial medical advancements that have transformed HIV into a manageable chronic condition for individuals, the ...

The UK is confronting a seismic demographic shift with an ageing population and declining fertility rates. In preparing for this change, it is critical that we shift how we think about health across ...

The glucagon-like peptide-1 (GLP-1) receptor agonist market is experiencing rapid growth, with more than 150 drug candidates currently in development as reported by Research & Markets, 2025. These ...

Long-acting (LA) therapies represent a significant innovation in pharmaceutical development by offering a sustained drug effect with reduced administration frequency. Realising the potential value of ...

Earlier this week, President Donald Trump signed an Executive Order to bring the prices Americans and U.S taxpayers pay for prescription drugs in line with those paid by similar nations. “President ...

In this Insights series, Around the World in HTAs, we shed light on HTA around the world. In this edition, Angela Kairu and Edwine Barasa of the KEMRI Wellcome Trust Research Programme, and Paul Oyalo ...